Oncology

SABCS 2025 showcases breakthroughs in breast cancer therapy, emphasizing novel therapies and precision medicine to enhance patient outcomes.

Pivotal FDA approvals in breast cancer treatment focus on precision medicine and innovative therapies in 2025.

Pharmacists enhance oncology care by guiding younger patients through precision diagnostics like ctDNA MRD testing, driving innovation in cancer treatment.

FDA approves a new combination therapy for BRCA2-mutated metastatic prostate cancer, showing significant efficacy in clinical trials.

Exploratory findings from the MONALEESA-3 trial presented at SABCS 2025 show ribociclib plus fulvestrant significantly enhances survival in ILC.

Discover how antibody drug conjugates (ADCs) are transforming treatment for HER2-positive breast cancer with brain metastases at SABCS 2025.

SABCS showcases emerging trends in breast cancer treatment, emphasizing pharmacists' vital role in medication management and patient care strategies.

Kelly Gable, professor and director of well-being and resilience at Southern Illinois University Edwardsville School of Pharmacy, discusses her own cancer journey and how pharmacists need to be more involved and proactive in patients' mental health.

Explore innovative biomarkers to enhance immunotherapy for early-stage TNBC, aiming to improve patient outcomes and treatment precision.

Explore the pleiotropic effects of GLP-1 agents in oncology care, highlighting their benefits and considerations for pharmacists and clinicians.

Latest findings presented at SABCS 2025 support trastuzumab deruxtecan's effectiveness and safety in treating HER2-positive breast cancer.

New research highlights the benefits of adding isatuximab to standard therapy for newly diagnosed multiple myeloma (NDMM), improving patient outcomes and quality of life.

Tucatinib enhances first-line maintenance therapy for HER2-positive metastatic breast cancer, improving progression-free survival and safety outcomes, as shown in the HER2CLIMB-05 trial.

Cell-cycle–focused CDK inhibitors offer new options for HR+/HER2– metastatic breast cancer after CDK4/6 resistance.

Pharmacists play a vital role in precision oncology, enhancing treatment decisions for metastatic breast cancer through genetic testing and targeted therapies.

Oral SERDs and combination therapies are redefining post-CDK4/6 treatment in HR+/HER2– metastatic breast cancer.

Explore innovative supplemental screening options for breast cancer, enhancing access and accuracy for women with dense breasts and inconclusive mammograms.

Discover how innovative imaging detection methods, including MRI and proteomics, enhance breast cancer screening and support pharmacists in patient care.

Exploratory analysis shows 1 in 4 patients maintain long-term response to ribociclib.

Teclistamab and daratumumab with hyaluronidase combination show significant efficacy in relapsed multiple myeloma (MM), potentially redefining treatment standards.

Explore the advancements and challenges of allogeneic CAR T-cell therapies, including immune rejection and innovative engineering strategies for cancer treatment.

Multidisciplinary approaches are crucial in treating complex cancer patients, focusing on tailored therapies and symptom management strategies.

Pharmacists play a crucial role in optimizing CAR-T therapy outcomes by guiding bridging therapy decisions and enhancing patient safety through proactive collaboration.

New research reveals that effective bridging therapy before cilta-cel infusion significantly enhances safety and long-term outcomes in patients with multiple myeloma.

In an analysis of the intention-to-treat population of the BENEFIT study, investigators demonstrated improved sustained minimal residual disease negativity with the Isa-VRd regimen in newly diagnosed multiple myeloma (NDMM).

Experts at the ASH Annual Meeting and Exposition in Orlando, Florida, explored innovative strategies and treatments for improving outcomes in diffuse large B-cell lymphoma.